Miguel F. Segura

Miguel F. Segura

Carlos Haya Avenue
Malaga, AN 29010, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

Journal: Pediatric blood & cancer

Published: May 04, 2026

A vitronectin-functionalized ECM-mimetic hydrogel platform for modelling integrin-dependent tumour responses to cilengitide.

A vitronectin-functionalized ECM-mimetic hydrogel platform for modelling integrin-dependent tumour responses to cilengitide.

Journal: Materials today. Bio

Published: February 10, 2026

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.

Journal: NPJ precision oncology

Published: December 18, 2025

Plasmid DNA Delivery Using a Stable Nanovesicle Platform: A Design-of-Experiments-Guided Investigation.

Plasmid DNA Delivery Using a Stable Nanovesicle Platform: A Design-of-Experiments-Guided Investigation.

Journal: ACS biomaterials science & engineering

Published: December 05, 2025

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches.

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches.

Journal: Epigenomics

Published: August 25, 2025

BORA overexpression promotes epithelial-mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease.

BORA overexpression promotes epithelial-mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease.

Journal: Clinical and translational medicine

Published: December 19, 2024

Advances in the approaches used to repurpose drugs for neuroblastoma.

Advances in the approaches used to repurpose drugs for neuroblastoma.

Journal: Expert opinion on drug discovery

Published: September 11, 2024

Long COVID-19: Impact of a personalized rehabilitation program.

Long COVID-19: Impact of a personalized rehabilitation program.

Journal: Rehabilitacion

Published: June 12, 2024

In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.

In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.

Journal: PloS one

Published: January 26, 2024

Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis.

Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis.

Journal: Clinical and translational medicine

Published: January 11, 2024

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma.

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma.

Journal: Experimental hematology & oncology

Published: December 13, 2023

Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients.

Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients.

Journal: Translational pediatrics

Published: July 17, 2023

Showing 1-12 of 77

Last Updated: 09/26/2026